Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

TRIUMEQ PD

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Standard Dose
EQ 60MG BASE;EQ 5MG BASE;30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TRIUMEQ PD is listed in Drugs@FDA under application 215413 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 60MG BASE;EQ 5MG BASE;30MG Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2025-10-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview TRIUMEQ PD is listed in Drugs@FDA under application 215413 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 60MG BASE;EQ 5MG BASE;30MG Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2025-10-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.